Scarica l'app Stockscreener
28.65
3.06%
0.85
Dopo l'orario di chiusura:
28.51
-0.14
-0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$27.80
Aprire:
$27.5
Volume 24 ore:
1.91M
Relative Volume:
0.82
Capitalizzazione di mercato:
$3.62B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-14.11
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+2.14%
1M Prestazione:
+18.10%
6M Prestazione:
+14.37%
1 anno Prestazione:
-24.17%
Intervallo 1D:
$27.26
$28.67
Intervallo di 1 settimana:
$27.14
$28.67
Portata 52W:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
28.65 | 3.56B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Can trapped investors hope for a rebound in Apellis Pharmaceuticals Inc.Buy Signal & Comprehensive Market Scan Insights - Newser
What’s the MACD signal for Apellis Pharmaceuticals Inc.Trade Risk Assessment & Weekly High Return Forecasts - khodrobank.com
Transcript : Apellis Pharmaceuticals, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 08 - MarketScreener
Analyzing net buyer seller activity in Apellis Pharmaceuticals Inc.July 2025 Gainers & Weekly High Conviction Trade Ideas - Newser
Apellis Pharmaceuticals Inc. stock retracement – recovery analysisJuly 2025 PostEarnings & Weekly Hot Stock Watchlists - Newser
What data driven models say about Apellis Pharmaceuticals Inc.’s futureEarnings Miss & Short-Term High Return Strategies - Newser
Published on: 2025-09-03 02:41:06 - Newser
Order flow analysis tools used on Apellis Pharmaceuticals Inc.Watch List & Consistent Growth Equity Picks - Newser
Can Apellis Pharmaceuticals Inc. deliver alphaEarnings Recap Summary & Verified Entry Point Signals - khodrobank.com
Should value investors consider Apellis Pharmaceuticals Inc.July 2025 News Drivers & Community Consensus Stock Picks - khodrobank.com
What’s the beta of Apellis Pharmaceuticals Inc. stockQuarterly Earnings Summary & Fast Entry Momentum Alerts - khodrobank.com
Key metrics from Apellis Pharmaceuticals Inc.’s quarterly dataJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - Newser
What’s the profit margin of Apellis Pharmaceuticals Inc.Dollar Strength & Real-Time Stock Movement Alerts - khodrobank.com
Is Apellis Set for a Rebound? - timothysykes.com
Is Apellis Pharmaceuticals Inc. stock a value trap2025 Earnings Impact & High Return Trade Guides - khodrobank.com
Will Apellis Pharmaceuticals Inc. stock recover after recent dropRecession Risk & Safe Capital Investment Plans - Newser
Is Apellis Pharmaceuticals Inc. meeting your algorithmic filter criteriaOptions Play & Consistent Profit Focused Trading Strategies - Newser
Published on: 2025-09-01 23:36:26 - Newser
Can machine learning forecast Apellis Pharmaceuticals Inc. recovery2025 Trading Recap & Low Risk High Reward Ideas - Newser
What to do if you’re stuck in Apellis Pharmaceuticals Inc.Market Activity Summary & Expert Verified Stock Movement Alerts - Newser
How cyclical is Apellis Pharmaceuticals Inc.’s revenue streamMarket Sentiment Report & Entry and Exit Point Strategies - khodrobank.com
Published on: 2025-09-01 19:43:22 - Newser
Real time social sentiment graph for Apellis Pharmaceuticals Inc.Quarterly Trade Review & Reliable Entry Point Alerts - Newser
Has Apellis Pharmaceuticals Inc. found a price floor2025 Market Outlook & Low Drawdown Momentum Trade Ideas - Newser
Apellis Pharmaceuticals Inc. Recovery Gathers Momentum on Chart Signals getLinesFromResByArray error: size == 0 - kangso.co.kr
Should I hold or sell Apellis Pharmaceuticals Inc. nowExit Point & Breakout Confirmation Trade Signals - khodrobank.com
Is Apellis Pharmaceuticals Inc. reversing from oversold territoryWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
How to track smart money flows in Apellis Pharmaceuticals Inc.July 2025 Trends & Precise Swing Trade Entry Alerts - Newser
Have Insiders Sold Apellis Pharmaceuticals Shares Recently? - simplywall.st
Automated trading signals detected on Apellis Pharmaceuticals Inc.Buy Signal & Safe Capital Investment Plans - Newser
Apellis Pharmaceuticals Inc. stock momentum explained2025 Top Gainers & Smart Allocation Stock Tips - Newser
What earnings revisions data tells us about Apellis Pharmaceuticals Inc.Stock Surge & Reliable Momentum Entry Alerts - Newser
Using fundamentals and technicals on Apellis Pharmaceuticals Inc.Weekly Trend Summary & Technical Entry and Exit Alerts - Newser
Heatmap analysis for Apellis Pharmaceuticals Inc. and competitorsQuarterly Earnings Summary & Intraday High Probability Setup Alerts - Newser
Can Apellis Pharmaceuticals Inc. recover in the next quarterJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - Newser
Signal strength of Apellis Pharmaceuticals Inc. stock in tech scannersPortfolio Return Report & Fast Gain Stock Trading Tips - Newser
What is Apellis Pharmaceuticals Inc.’s valuation compared to sectorM&A Rumor & Technical Confirmation Alerts - sundaytimes.kr
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):